Trial reportScientific reports2018
Fluoxetine does not enhance the effect of perceptual learning on visual function in adults with amblyopia.
Trial report in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07226141 (Valproate for the Treatment of Residual Amblyopia), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Valproate for the Treatment of Residual Amblyopia
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Selective serotonin reuptake inhibitors for amblyopia treatment: a systematic review and meta-analysis of randomized controlled trials.Frontiers in neurologyPooled it
- Durable recovery from amblyopia with donepezil.Scientific reports · 2023Trial
- The Effect of Combined Patching and Citalopram on Visual Acuity in Adults with Amblyopia: A Randomized, Crossover, Placebo-Controlled Trial.Neural plasticity · 2019Trial
- Systematic Review and Meta-Analysis of RCTs on Efficacy of Conventional vs. Emerging Treatments for Amblyopia.Life (Basel, Switzerland) · 2026Review
- Understanding amblyopia from the perspective of neurovascular units: changes in the retina and brain.Frontiers in cell and developmental biology · 2025Review
- The relationship between visual acuity loss and GABAergic inhibition in amblyopia.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Comprehensive review of amblyopia: Types and management.Indian journal of ophthalmology · 2023Review
- Metaplasticity: a key to visual recovery from amblyopia in adulthood?Current opinion in ophthalmology · 2022Review
- Article
- Cortical Tuning is Impaired After Perceptual Experience in Primary Visual Cortex of Serotonin Transporter-Deficient Mice.Cerebral cortex communications · 2020Article
- Characterization, passive and active treatment in strabismic amblyopia: a narrative review.International journal of ophthalmology · 2020Review
- Selective serotonin reuptake inhibitors may lead to improved cataract surgery outcomes in patients with amblyopia.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- From Basic Visual Science to Neurodevelopmental Disorders: The Voyage of Environmental Enrichment-Like Stimulation.Neural plasticity · 2019Review
- Leveraging neural plasticity for the treatment of amblyopia.Survey of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amblyopia is a common visual disorder that is treatable in childhood. However, therapies have limited efficacy in adult patients with amblyopia. Fluoxetine can reinstate early-life critical period-like neuronal plasticity and has been used to recover functional vision in adult rats with amblyopia. We conducted a Phase 2, randomized (fluoxetine vs. placebo), double-blind, multicenter clinical trial examined whether or not fluoxetine can improve visual acuity in amblyopic adults. This interventional trial included 42 participants diagnosed with moderate to severe amblyopia. Subjects were randomized to receive either 20 mg fluoxetine (n = 22) or placebo (n = 20). During the 10-week treatment period, all subjects performed daily computerized perceptual training and eye patching. At the primary endpoint, the mean treatment group difference in visual acuity improvement was only 0.027 logMAR units (95% CI: -0.057 to 0.110; p = 0.524). However, visual acuity had significantly improved from baseline to 10 weeks in both fluoxetine (-0.167 logMAR; 95% CI: -0.226 to -0.108; p < 0.001) and placebo (-0.194 logMAR; 95% CI: -0.254 to -0.133; p < 0.001) groups. While this study failed to provide evidence that fluoxetine enhances neuroplasticity, our data support other recent clinical studies suggesting that improvement of vision can be accomplished in adults with amblyopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.